Zika virus (ZIKV) is associated with neonatal microcephaly and Guillain–Barré syndrome1,2. While progress has been made in understanding the causal link between ZIKV infection and microcephaly3,4,5,6,7,8,9, the life cycle and pathogenesis of ZIKV are less well understood. In particular, there are conflicting reports on the role of AXL, a TAM family kinase receptor that was initially described as the entry receptor for ZIKV10,11,12,13,14,15,16,17,18,19,20,21,22. Here, we show that while genetic ablation of AXL protected primary human astrocytes and astrocytoma cell lines from ZIKV infection, AXL knockout did not block the entry of ZIKV. We found, instead, that the presence of AXL attenuated the ZIKV-induced activation of type I interferon (IFN) signalling genes, including several type I IFNs and IFN-stimulating genes. Knocking out type I IFN receptor α chain (IFNAR1) restored the vulnerability of AXL knockout astrocytes to ZIKV infection. Further experiments suggested that AXL regulates the expression of SOCS1, a known type I IFN signalling suppressor, in a STAT1/STAT2-dependent manner. Collectively, our results demonstrate that AXL is unlikely to function as an entry receptor for ZIKV and may instead promote ZIKV infection in human astrocytes by antagonizing type I IFN signalling.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Brasil, P. et al. Zika virus infection in pregnant women in Rio de Janeiro. N. Engl. J. Med. 375, 2321–2334 (2016).

  2. 2.

    Parra, B. et al. Guillain-Barre syndrome associated with Zika virus infection in Colombia. N. Engl. J. Med. 375, 1513–1523 (2016).

  3. 3.

    Tang, H. et al. Zika virus infects human cortical neural progenitors and attenuates their growth. Cell Stem Cell 18, 587–590 (2016).

  4. 4.

    Garcez, P. P. et al. Zika virus impairs growth in human neurospheres and brain organoids. Science 352, 816–818 (2016).

  5. 5.

    Qian, X. et al. Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. Cell 165, 1238–1254 (2016).

  6. 6.

    Miner, J. J. et al. Zika virus infection during pregnancy in mice causes placental damage and fetal demise. Cell 165, 1081–1091 (2016).

  7. 7.

    Cugola, F. R. et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 534, 267–271 (2016).

  8. 8.

    Li, H. et al. Zika virus infects neural progenitors in the adult mouse brain and alters proliferation. Cell Stem Cell 19, 593–598 (2016).

  9. 9.

    Adams Waldorf, K. M. et al. Fetal brain lesions after subcutaneous inoculation of Zika virus in a pregnant nonhuman primate. Nat. Med. 22, 1256–1259 (2016).

  10. 10.

    Meertens, L. et al. The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe 12, 544–557 (2012).

  11. 11.

    Miner, J. J. et al. The TAM receptor Mertk protects against neuroinvasive viral infection by maintaining blood-brain barrier integrity. Nat. Med. 21, 1464–1472 (2015).

  12. 12.

    Hamel, R. et al. Biology of Zika Virus infection in human skin cells. J. Virol. 89, 8880–8896 (2015).

  13. 13.

    Retallack, H. et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc. Natl Acad. Sci. USA 113, 14408–14413 (2016).

  14. 14.

    Savidis, G. et al. Identification of Zika virus and Dengue virus dependency factors using functional genomics. Cell Rep. 16, 232–246 (2016).

  15. 15.

    Nowakowski, T. J. et al. Expression analysis highlights AXL as a candidate Zika virus entry receptor in neural stem cells. Cell Stem Cell 18, 591–596 (2016).

  16. 16.

    Tabata, T. et al. Zika virus targets different primary human placental cells, suggesting two routes for vertical transmission. Cell Host Microbe 20, 155–166 (2016).

  17. 17.

    Ma, W. et al. Zika virus causes testis damage and leads to male infertility in mice. Cell 167, 1511–1524 (2016).

  18. 18.

    Wells, M. F. et al. Genetic ablation of AXL does not protect human neural progenitor cells and cerebral organoids from Zika virus infection. Cell Stem Cell 19, 703–708 (2016).

  19. 19.

    Miner, J. J. et al. Zika virus infection in mice causes panuveitis with shedding of virus in tears. Cell Rep. 16, 3208–3218 (2016).

  20. 20.

    Hastings, A. K. et al. TAM receptors are not required for Zika virus infection in mice. Cell Rep. 19, 558–568 (2017).

  21. 21.

    Li, F. et al. AXL is not essential for Zika virus infection in the mouse brain. Emerg. Microbes Infect. 6, e16 (2017).

  22. 22.

    Govero, J. et al. Zika virus infection damages the testes in mice. Nature 540, 438–442 (2016).

  23. 23.

    Grant, A. et al. Zika virus targets human STAT2 to inhibit type I interferon signaling. Cell Host Microbe 19, 882–890 (2016).

  24. 24.

    Kumar, A. et al. Zika virus inhibits type-I interferon production and downstream signaling. EMBO Rep. 17, 1766–1775 (2016).

  25. 25.

    Khan, S. et al. Dampened antiviral immunity to intravaginal exposure to RNA viral pathogens allows enhanced viral replication. J. Exp. Med. 213, 2913–2929 (2016).

  26. 26.

    Meertens, L. et al. Axl mediates ZIKA virus entry in human glial cells and modulates innate immune responses. Cell Rep. 18, 324–333 (2017).

  27. 27.

    Rausch, K. et al. Screening bioactives reveals nanchangmycin as a broad spectrum antiviral active against Zika virus. Cell Rep. 18, 804–815 (2017).

  28. 28.

    Liu, S., DeLalio, L. J., Isakson, B. E. & Wang, T. T. AXL-mediated productive infection of human endothelial cells by Zika virus. Circ. Res. 119, 1183–1189 (2016).

  29. 29.

    Lindqvist, R. et al. Fast type I interferon response protects astrocytes from flavivirus infection and virus-induced cytopathic effects. J. Neuroinflamm. 13, 277 (2016).

  30. 30.

    Hussmann, K. L., Vandergaast, R., Zheng, K., Hoover, L. I. & Fredericksen, B. L. Structural proteins of West Nile virus are a major determinant of infectious particle production and fitness in astrocytes. J. Gen. Virol. 95, 1991–2003 (2014).

  31. 31.

    Hussmann, K. L., Samuel, M. A., Kim, K. S., Diamond, M. S. & Fredericksen, B. L. Differential replication of pathogenic and nonpathogenic strains of West Nile virus within astrocytes. J. Virol. 87, 2814–2822 (2013).

  32. 32.

    Palus, M. et al. Infection and injury of human astrocytes by tick-borne encephalitis virus. J. Gen. Virol. 95, 2411–2426 (2014).

  33. 33.

    van den Pol, A. N., Mao, G., Yang, Y., Ornaghi, S. & Davis, J. N. Zika virus targeting in the developing brain. J. Neurosci. 37, 2161–2175 (2017).

  34. 34.

    Deng, Y. Q. et al. Isolation, identification and genomic characterization of the Asian lineage Zika virus imported to China. Sci. China Life Sci. 59, 428–430 (2016).

  35. 35.

    Perera-Lecoin, M., Meertens, L., Carnec, X. & Amara, A. Flavivirus entry receptors: an update. Viruses 6, 69–88 (2014).

  36. 36.

    Sasaki, T. et al. Structural basis for Gas6-Axl signalling. EMBO J. 25, 80–87 (2006).

  37. 37.

    Rothlin, C. V., Ghosh, S., Zuniga, E. I., Oldstone, M. B. & Lemke, G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131, 1124–1136 (2007).

  38. 38.

    Bhattacharyya, S. et al. Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe 14, 136–147 (2013).

  39. 39.

    Porritt, R. A. & Hertzog, P. J. Dynamic control of type I IFN signalling by an integrated network of negative regulators. Trends Immunol. 36, 150–160 (2015).

  40. 40.

    Yockey, L. J. et al. Vaginal exposure to Zika virus during pregnancy leads to fetal brain infection. Cell 166, 1247–1256 e1244 (2016).

  41. 41.

    Lazear, H. M. et al. A mouse model of Zika virus pathogenesis. Cell Host Microbe 19, 720–730 (2016).

  42. 42.

    Cho, H., Shrestha, B., Sen, G. C. & Diamond, M. S. A role for IFIT2 in restricting West Nile virus infection in the brain. J. Virol. 87, 8363–8371 (2013).

  43. 43.

    Wang, Z. Y. et al. Axl is not an indispensable factor for Zika virus infection in mice. J. Gen. Virol. 98, 2061–2068 (2017).

  44. 44.

    Jagger, B. W. et al. Gestational stage and IFN-λ signaling regulate ZIKV infection in utero. Cell Host Microbe 22, 366–376 e363 (2017).

  45. 45.

    Wu, T. D. & Nacu, S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics 26, 873–881 (2010).

  46. 46.

    Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).

  47. 47.

    Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).

  48. 48.

    Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289–300 (1995).

  49. 49.

    Eden, E., Navon, R., Steinfeld, I., Lipson, D. & Yakhini, Z. GOrilla: A tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinform. 10, 48 (2009).

  50. 50.

    Supek, F., Bosnjak, M., Skunca, N. & Smuc, T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS ONE 6, e21800 (2011).

  51. 51.

    Cheadle, C., Vawter, M. P., Freed, W. J. & Becker, K. G. Analysis of microarray data using Z score transformation. J. Mol. Diagn. 5, 73–81 (2003).

Download references


This work was supported by the National Science Foundation of China (81430030 to J.X.), the ShanghaiTech University Startup Fund (to B.J. and J.L.), the Shanghai Public Health Clinical Center (to X.Z.), the Developmental Center of Shanghai Shenkang Hospital (SHDC12014104 to X.Z.) and the Shanghai Advanced Biosafety and Pathogen Diagnostic Platform (15DZ2290200 to X.Z.).

Author information

Author notes

  1. Jian Chen and Yi-feng Yang contributed equally to this work

  2. Deceased: Yunwen Hu.


  1. Scientific Research Center, Shanghai Public Health Clinical Center & Institutes of Biomedical Sciences, Key Laboratory of Medical Molecular Virology of Ministry of Education/Health, Shanghai Medical College, Fudan University, Shanghai, China

    • Jian Chen
    • , Yu Yang
    • , Peng Zou
    • , Yongquan He
    • , Ru Bai
    • , Yunwen Hu
    • , Lu Lu
    • , Xiaoyan Zhang
    •  & Jianqing Xu
  2. Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China

    • Yi-feng Yang
    • , Sai-lan Shui
    • , Yan-ru Cui
    • , Ya-jun Liang
    • , Biao Jiang
    •  & Jia Liu
  3. Department of Ecology and Genetics, Evolutionary Biology Centre, Uppsala University, Uppsala, Sweden

    • Jun Chen
  4. State Key Laboratory for Infectious Disease Prevention and Control, China Centers for Disease Control and Prevention, Beijing, China

    • Xiaoyan Zhang
    •  & Jianqing Xu


  1. Search for Jian Chen in:

  2. Search for Yi-feng Yang in:

  3. Search for Yu Yang in:

  4. Search for Peng Zou in:

  5. Search for Jun Chen in:

  6. Search for Yongquan He in:

  7. Search for Sai-lan Shui in:

  8. Search for Yan-ru Cui in:

  9. Search for Ru Bai in:

  10. Search for Ya-jun Liang in:

  11. Search for Yunwen Hu in:

  12. Search for Biao Jiang in:

  13. Search for Lu Lu in:

  14. Search for Xiaoyan Zhang in:

  15. Search for Jia Liu in:

  16. Search for Jianqing Xu in:


J.X. and J.L. conceived this study. Jian C., Y.-F.Y., B.J., X.Z., J.L. and J.X. designed the experiments. Jian C., Y.-F.Y., Y.Y., Yongquan H., S.-L.S., Y.-R.C., R.B., Y.-J.L. and J.L. performed the experiments. P.Z., Yunwen H. and L.L. prepared the ZIKV. Jun C. analysed the RNA-Seq data. Jian C., Y.-F.Y., J.L. and J.X. prepared the manuscript.

Competing interests

The authors declare that they have no competing financial interests.

Corresponding authors

Correspondence to Xiaoyan Zhang or Jia Liu or Jianqing Xu.

Supplementary information

  1. Supplementary Information

    Supplementary Figures 1–11, Supplementary Table 1 and Supplementary Notes.

  2. Life Sciences Reporting Summary

About this article

Publication history




Issue Date



Further reading